KRAS and cancer: To further investigate the effect of KRAS and TP53 mutation status on the differentially expressed cancer driver pathways, we subset the TCGA and CCLE datasets to samples carrying a non-silent KRAS or TP53 mutation and repeated the SVM analysis (see “Methods”).